US Stock Move | Pneumococcal vaccine achieves late-stage clinical trial target, Vaxcyte (PCVX.US) opens more than 50% higher
On Monday, Vaxcyte (PCVX.US) soared more than 50% at the open and was up approximately 53% at the time of writing, with a market capitalization of 12.8 billions USD.
According to Zhihu Finance APP, on Monday, Vaxcyte (PCVX.US) opened more than 50% higher, and as of press time, the share price had risen about 53%, with a market value of $12.8 billion. According to reports, the company's pneumococcal vaccine reached its late-stage clinical trial goals. Based on the company’s evaluation, VAX-31—a 31-valent pneumococcal conjugate vaccine still in the research phase—achieved positive topline results in the pivotal Phase III OPUS-1 trial. This trial evaluated the candidate vaccine’s safety, tolerability, and immunogenicity in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia. In the OPUS-1 trial, VAX-31 met all pre-specified co-primary immunogenicity endpoints in subjects aged 50 and above. These trial results will establish the foundation for the upcoming Biologics License Application submission to the U.S. Food and Drug Administration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Alstom rises by 6%
Is the Stock Market in Denial? Michael Burry Points to 2000 and 2008
BUZZ-Freshworks stock rises ahead of inclusion in S&P SmallCap 600 Index
October 6 — Software development company Freshworks Inc (FRSH.O) saw its shares rise by 4.3% to $13.79 in pre-market trading. The company will replace BioLife Solutions (BLFS.O) in the S&P SmallCap 600 Index, effective before market open on October 8, according to an announcement released after the U.S. stock market closed on Monday. BLFS is set to be acquired later this year by Repligen Corp (RGEN.O), pending regulatory and shareholder approval. According to data from London Stock Exchange Group (LSEG), as of the previous trading session's close, FRSH had a market value of $3.45 billions. As of the last close, the stock had gained 7.9% so far this year. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translations and provides them for the convenience of readers only. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation features.)
ECB’s Rehn: High long-term rates contributing to a slowdown in growth
Crypto prices
More
